Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copaxone Reaches MS Market Share High Following Tysabri Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.

You may also be interested in...



Copaxone Growth Helps Teva Offset Declining Generics Business

Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.

Copaxone Growth Helps Teva Offset Declining Generics Business

Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.

Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal

Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel